Yorkville Advisors LLC (YA)

www.yorkvilleadvisors.com

Foreign Private Equity Fund

Tech Verticals Preferences

Artificial Intelligence, Augmented Reality, Biotechnology, Data Analytics, DevOps, Digital Media, Energy Tech, Enterprise Applications, Entertainment, Hardware, Healthtech, Industrial Technologies, Industry 4.0, IoT, Machine Learning, Medical Cannabis, Medical Devices, MedTech, Mobile Applications, Mobile infrastructure, Optical Networking, Semiconductors, Smart City, Software Technologies, Sustainability, Testing, Therapeutics, Travel Tech, Wearables, Wireless Infrastructure

General Data

Current Active Portfolio Companies:

DESCRIPTION

Yorkville Advisors is a global investment manager that oversees a variety of private investment funds. The company allocates its funds' capital through tailored structured debt and equity investments. The investment criteria of Yorkville Advisors centers around management teams, business fundamentals, and stock trading metrics. The funds managed by Yorkville Advisors have expansive investment mandates that span across various sectors and geographies. Often, they serve as the exclusive investor in a capital raise, enabling a controlled and disciplined exit strategy.
The team has been providing growth and acquisition capital to public companies since 2001. That experience has given them unique insight, allowing them the opportunity to tailor their investment products to the unique needs of their portfolio companies.

CONTACT INFO

Expand / Collapse All

Main Address: Jersey City, United States

Address	1012 Springfield Ave.
City	Jersey City
State/Province	NJ
Country	United States
Zip	07092

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Mr. Mark Angelo	President & Partner

Investment Data

Managed Capital

abCDe

Preferences

Type of Financing	Equity,Loans - Straight,Straight Equity
Stage Preferences	Initial Revenues,Revenue Growth

SECTOR SEGMENTATION (By Number Of Companies)

Biomed

30%

Medical Devices

31%

Hardware & Industrial

15%

Network Infrastructure

Semiconductors

Consumer-Oriented Software

	PORTFOLIO COMPANIES

Current Portfolio Companies (15)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

ALON USA

N/A

PIPE

24/01/2011

$25m

N/A

Averbuch

N/A

PIPE

01/09/2009

$15m

N/A

Credit line; Standby Equity Distribution Agreement (SEDA)

BOS

BOS is a provider of RFID and Mobile solutions and a global provider of Supply Chain solutions to enterprises. BOS' RFID and Mobile division offers both turnkey integration services, as well as stand-alone products, including RFID and AIDC hardware and communications equipment, BOS middleware and industry-specific software applications. The company's Supply Chain division provides electronic components consolidation services to the aerospace, defense, medical and telecommunications industries, as well as to enterprise customers worldwide

Network Infra.

PIPE

20/06/2013

$0.6m

Invested in the company's ordinary shares over two years in a Standby Equity Distribution Agreement (SEDA).

Brainsway

PIPE

21/12/2008

$15m

Credit line; Standby Equity Distribution Agreement (SEDA). Brainsway can draw up to $0.4m at a time with at least ten business days between each withdrawal.

D-Medical Industries

N/A

PIPE

17/04/2011

$20m

N/A

By way of a standby equity-line.

Indaptus Therapeutics

Biomed

PIPE

25/07/2011

$12m

By way of a standby equity-line, over the next 3 years, against the allocation of company shares, and following the fulfillment of prior conditions.

InsuLine

PIPE

11/09/2013

$10m

Reverse Equity Pricing Agreement (REPA).

Kaman Trade

N/A

PIPE

07/04/2011

$5m

N/A

By way of a standby equity-line.

Pangaea

N/A

PIPE

01/07/2009

$17m

N/A

By way of a standby equity-line.

Purple Biotech

Biomed

PIPE

21/11/2013

$10m

Reverse Equity Pricing Agreement (REPA).

Samsara Luggage

HW & Indust.

First Round

06/06/2019

$1.6m

Scinai Immunotherapeutics

Biomed

PIPE	12/06/2025	$1.4m	$1.4m
Debt Financing	25/02/2010	$15m	$15m	Credit line; Standby Equity Distribution Agreement (SEDA)

Tower Semiconductor

Semicon.

PIPE	16/12/2010	$35m	$35m	By way of a standby equity-line.
PIPE	25/04/2010	$35m	$35m	By way of a standby equity-line.
PIPE	12/08/2009	$25m	$25m	By way of a standby equity-line.

Vaxil

Biomed

PIPE

10/07/2013

$3m

Reverse Equity Pricing Agreement (REPA).

Wearable Devices

HW & Indust.

PIPE

07/06/2024

$2m

Through managed fund YA II PN.

Exits (7)

Company Name	Exit Type	Date Announced	Amount	Remarks
abC Defghij	Acquired	03/09/2013	abCDe
abC Defghij	Acquired	19/06/2016	abCDe
abC Defghij (Traditional Industry)	Acquired	05/07/2011	abCDe	Purchased 100% of the company with Anglo-Peacock Nominees for a total price of NIS 25m. Kedma's investment was made through its subsidiary, Brand Industries. It holds 50.1% of the company.
abC Defghij	Merged	08/04/2018	abCDe	Share swap deal. InsuLine maintained its name and Life Sciences activity in the first year, alongside a new financing activity. 06/2019: InsuLine changed its name to Erech Finance Cahalacha and its main activity became financing.
abC Defghij	Acquired	21/09/2018	abCDe	In cash. The acquisition is expected to close in 01/2019, subject to customary closing conditions including receipt of regulatory clearances and approval by Mazor's shareholders.
abC Defghij	Acquired	08/11/2017	abCDe	Purchased 75% of the shelf company and control of it for 1.15m NIS. Following the purchase, the company merged new non high-tech activity into it, by acquiring 51% of Hi-Pharma, an Israeli company dealing in growing and selling cannabis.
abC Defghij	Acquired	24/06/2013	abCDe

Historic Portfolio (2)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

Galten

Ceased to Operate

Energy

PIPE

01/08/2012

$5m

Through a Standby Equity Purchase Agreement (SEPA) by Yorkville unit YA Global Investments LP.

Orckit Corrigent

Ceased to Operate

Network Infra.

PIPE

04/08/2010

$10m

By way of a standby 3-years equity line.

Last Updated:	abCDe
IVC Number:	abCDe